Mizuho raised the firm’s price target on Harmony Biosciences to $33 from $28 and keeps a Buy rating on the shares post the Q3 report. The analyst cites renewed confidence in the company’s ability to add patients onto Wakix therapy for the target raise.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HRMY:
- Harmony Biosciences board authorizes $200M share repurchase program
- Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results
- Harmony Biosciences reports Q3 adjusted EPS 97c, consensus 65c
- Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings Cheat Sheet
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
